Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LTR PharmaASX:LTP -2.00%6 Days Sales Outstanding is 630.12 as of Dec. 2025, which is 6201% above its 10-year median of 10.00. GuruFocus rates ASX:LTP with a GF Score™ of 6/100. Among 835 Biotechnology companies, LTR Pharma ranks worse than 96.41% on this metric.
LTR Pharma's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$0.26 Mil. LTR Pharma's Revenue for the
six
months ended in Dec. 2025 was A$0.07 Mil.
Hence, LTR Pharma's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 630.12.
The historical rank and industry rank for LTR Pharma's Days Sales Outstanding or its related term are showing as below:
ASX:LTP'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 10 Med: 10 Max: 853.99
Current: 853.99
During the past 5 years, LTR Pharma's highest Days Sales Outstanding was 853.99. The lowest was 10.00. And the median was 10.00.
ASX:LTP's Days Sales Outstanding is ranked worse than 96.41% of 835
companies
in the Biotechnology industry
Industry Median: 68.94
vs ASX:LTP: 853.99
LTR Pharma's Days Sales Outstanding
declined
from Dec. 2024 (1,712.02) to Dec. 2025 (630.12).
LTR Pharma (ASX:LTP) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
LTR Pharma Days Sales Outstanding Related Terms
LTR Pharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for LTR Pharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LTP vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, LTR Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where LTR Pharma's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 630.12 mean?
LTR Pharma (ASX:LTP) has a Days Sales Outstanding of 630.12 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on LTR Pharma and its competitors. This is 6201% above median its historical median of 10.00. Over the past decade, LTR Pharma's Days Sales Outstanding has ranged from 10.00 to 853.99. According to the industry distribution chart, LTR Pharma ranks #805 out of 835 companies in the Biotechnology industry, placing it in the top 96.4%.
Is LTR Pharma's Days Sales Outstanding too high?
LTR Pharma's current Days Sales Outstanding of 630.12 is 6201% above median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 853.99. The Biotechnology industry median Days Sales Outstanding is 68.94. LTR Pharma's value of 630.12 is 814% above this industry median. Based on the distribution chart, LTR Pharma ranks #805 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, LTR Pharma has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #805 out of 835 companies for Days Sales Outstanding. This places LTR Pharma in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. LTR Pharma's value of 630.12 is 814% above this benchmark. Historically, LTR Pharma's own Days Sales Outstanding has ranged from 10.00 to 853.99 over the past decade. While the company's 10-year median is 10.00 vs. the industry median of 68.94, LTR Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LTR Pharma's current Days Sales Outstanding of 630.12 is 814% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on LTR Pharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LTR Pharma's current Days Sales Outstanding is 630.12, which is 6201% above median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Days Sales Outstanding of 630.12. The current Days Sales Outstanding is 630.12, which is 6201% above median its 10-year median of 10.00 and 814% above the Biotechnology industry median of 68.94. LTR Pharma's overall GF Score™ is 6/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Days Sales Outstanding is 630.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
6GF Score
Get the complete analysis for ASX:LTP
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 
